Mai, Julia
Lachinov, Dmitrii
Riedl, Sophie
Reiter, Gregor S.
Vogl, Wolf-Dieter
Bogunovic, Hrvoje
Schmidt-Erfurth, Ursula
Article History
Received: 20 January 2023
Accepted: 25 April 2023
First Online: 29 April 2023
Competing interests
: The FILLY Phase 2 study was conducted by Apellis Pharmaceuticals and our work was in part supported by an Apellis research grant. The organisation had no role in the design and conduct of this research. Gregor S. Reiter: RetInSight: Grant funding, Hrvoje Bogunovic: Contract Research to the Medical University of Vienna: Apellis, Heidelberg Engineering, Ursula Schmidt-Erfurth: Scientific Consultant: Genentech, Heidelberg, Kodiak, Novartis, RetInSight, Roche, Contract Research to the Medical University of Vienna: Apellis, Genentech, Kodiak. Julia Mai, Dmitrii Lachinov, Sophie Riedl, Wolf-Dieter Vogl: No financial disclosures.